http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112603918-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40 |
| filingDate | 2020-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-112603918-B |
| titleOfInvention | Application of kappa-opioid receptor agonist U50,488H in preparation of medicines for treating vascular calcification |
| abstract | The invention belongs to the technical field of medicines, relates to a new application of a kappa-opioid receptor agonist U50,488H, and more particularly relates to an application of a kappa-opioid receptor agonist U50,488H in preparation of a medicine for treating vascular calcification. Through reducing the expression of PFKFB3, the glycolysis level is further inhibited, so that the calcification of VSMCs induced by high phosphorus is inhibited, and the research result provides a potential drug target and a treatment strategy for clinical treatment of vascular calcification. |
| priorityDate | 2020-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 50.